Trial
NCT04576208
A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Takeda
Collaborators
—
Condition
Non-Small Cell Lung Cancer (NSCLC)
Intervention
TAK-788
Why stopped
Business Decision (no safety or efficacy concerns)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-17